Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study.

IF 3.2 Q2 ONCOLOGY JCO Global Oncology Pub Date : 2024-11-01 Epub Date: 2024-11-14 DOI:10.1200/GO-24-00281
Fisihatsion Tadesse, Francesco Sparano, Amha Gebremedhin, Abdulaziz Abubeker, Alfonso Piciocchi, Marta Cipriani, Daniela Krepper, Lalise Gemechu, Atalay Mulu, Getahun Asres, Fabio Efficace
{"title":"Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study.","authors":"Fisihatsion Tadesse, Francesco Sparano, Amha Gebremedhin, Abdulaziz Abubeker, Alfonso Piciocchi, Marta Cipriani, Daniela Krepper, Lalise Gemechu, Atalay Mulu, Getahun Asres, Fabio Efficace","doi":"10.1200/GO-24-00281","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Health-related quality of life (HRQoL) is now an important goal of therapy for patients with chronic myeloid leukemia (CML). However, there is paucity of data for patients living in low-income countries (LICs) and on factors associated with their HRQoL profile. The primary objective was to compare the HRQoL of patients with CML living in an LIC (Ethiopia) with that of patients living in a high-income country (HIC).</p><p><strong>Methods: </strong>Adult patients with CML treated with tyrosine kinase inhibitors in Ethiopia were considered eligible for this study. To assess their HRQoL and symptom burden, eligible patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the EORTC Quality of Life Questionnaire Chronic Myeloid Leukemia 24 (QLQ-CML24). A matched case-control analysis was applied to compare the HRQoL profile of the herein-recruited Ethiopian cohort with a sample of patients with CML from an HIC (Italy).</p><p><strong>Results: </strong>Overall, 395 Ethiopian patients were enrolled between February 2021 and June 2021. Except for dyspnea and satisfaction with care, the Ethiopian patients reported lower HRQoL and functioning and higher symptom burden compared with patients with CML living in an HIC. A remarkable proportion of Ethiopian patients (n = 353, 89.4%) reported financial toxicity (FT). Compared with patients without FT, those with FT reported a higher prevalence of clinically important problems and symptoms across all the QLQ-C30 scales. For example, the prevalence of clinically important impairment of social functioning was almost sixfold higher for patients with FT compared with those without FT (41.8%, 7.1%, respectively).</p><p><strong>Conclusion: </strong>Our results indicate that the HRQoL profile of patients with CML living in Ethiopia may be worse across several important functional and symptom domains than that of their peers living in an HIC. In addition, FT is highly prevalent among these patients and it is associated with poorer HRQoL outcomes.</p>","PeriodicalId":14806,"journal":{"name":"JCO Global Oncology","volume":"10 ","pages":"e2400281"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO Global Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/GO-24-00281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Health-related quality of life (HRQoL) is now an important goal of therapy for patients with chronic myeloid leukemia (CML). However, there is paucity of data for patients living in low-income countries (LICs) and on factors associated with their HRQoL profile. The primary objective was to compare the HRQoL of patients with CML living in an LIC (Ethiopia) with that of patients living in a high-income country (HIC).

Methods: Adult patients with CML treated with tyrosine kinase inhibitors in Ethiopia were considered eligible for this study. To assess their HRQoL and symptom burden, eligible patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the EORTC Quality of Life Questionnaire Chronic Myeloid Leukemia 24 (QLQ-CML24). A matched case-control analysis was applied to compare the HRQoL profile of the herein-recruited Ethiopian cohort with a sample of patients with CML from an HIC (Italy).

Results: Overall, 395 Ethiopian patients were enrolled between February 2021 and June 2021. Except for dyspnea and satisfaction with care, the Ethiopian patients reported lower HRQoL and functioning and higher symptom burden compared with patients with CML living in an HIC. A remarkable proportion of Ethiopian patients (n = 353, 89.4%) reported financial toxicity (FT). Compared with patients without FT, those with FT reported a higher prevalence of clinically important problems and symptoms across all the QLQ-C30 scales. For example, the prevalence of clinically important impairment of social functioning was almost sixfold higher for patients with FT compared with those without FT (41.8%, 7.1%, respectively).

Conclusion: Our results indicate that the HRQoL profile of patients with CML living in Ethiopia may be worse across several important functional and symptom domains than that of their peers living in an HIC. In addition, FT is highly prevalent among these patients and it is associated with poorer HRQoL outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受酪氨酸激酶抑制剂治疗的埃塞俄比亚慢性粒细胞白血病患者与健康相关的生活质量和经济负担:一项横断面研究。
目的:与健康相关的生活质量(HRQoL)现已成为慢性髓性白血病(CML)患者治疗的一个重要目标。然而,生活在低收入国家(LICs)的患者及其 HRQoL 相关因素的数据却很少。研究的主要目的是比较生活在低收入国家(埃塞俄比亚)的 CML 患者与生活在高收入国家(HIC)的患者的 HRQoL:埃塞俄比亚接受酪氨酸激酶抑制剂治疗的成年 CML 患者被认为符合本研究的条件。为了评估他们的 HRQoL 和症状负担,符合条件的患者填写了欧洲癌症研究和治疗组织生活质量问卷-核心 30 (EORTC QLQ-C30) 和 EORTC 生活质量问卷慢性粒细胞白血病 24 (QLQ-CML24)。我们采用了匹配病例对照分析法,以比较在此招募的埃塞俄比亚队列与来自高收入国家(意大利)的慢性粒细胞白血病患者样本的 HRQoL 情况:2021年2月至2021年6月期间,共招募了395名埃塞俄比亚患者。与生活在高收入国家的 CML 患者相比,除了呼吸困难和对护理的满意度外,埃塞俄比亚患者的 HRQoL 和功能较低,症状负担较重。很大一部分埃塞俄比亚患者(n = 353,89.4%)报告了经济毒性(FT)。与没有财务毒性的患者相比,有财务毒性的患者在所有 QLQ-C30 量表中报告的临床重要问题和症状的发生率更高。例如,与无 FT 患者相比,有 FT 患者的临床重要社会功能损害发生率几乎高出六倍(分别为 41.8%、7.1%):我们的研究结果表明,与生活在高收入国家的同龄人相比,生活在埃塞俄比亚的 CML 患者在几个重要功能和症状领域的 HRQoL 情况可能更差。此外,FT 在这些患者中非常普遍,而且与较差的 HRQoL 结果有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JCO Global Oncology
JCO Global Oncology Medicine-Oncology
CiteScore
6.70
自引率
6.70%
发文量
310
审稿时长
7 weeks
期刊最新文献
Beliefs on Causes of Cancer in the General Population, and the Association With Risk Perception and Lifestyle in a Multiethnic Setting. Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial. Evaluation of the Stronger Together Peer Mentoring Model Among Patients With Breast and Gynecologic Cancer in Viet Nam. Germline Genetic Susceptibility Testing Among Emirati Nationals at Risk for Hereditary Breast and Ovarian Cancer Syndrome. Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1